Dr. Reddy's Laboratories Limited (RDY)
NYSE: RDY · Real-Time Price · USD
13.83
-0.09 (-0.65%)
May 1, 2025, 4:00 PM EDT - Market closed
Dr. Reddy's Laboratories Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Dr. Reddy's Laboratories stock has a target of 17, which predicts an increase of 22.92% from the current stock price of 13.83.
Analyst Consensus: Buy
* Price targets were last updated on Nov 6, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for Dr. Reddy's Laboratories is "Buy". This means that the analyst believes this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $17 → $17 | Buy | Maintains | $17 → $17 | +22.92% | Nov 6, 2024 |
| Barclays | Barclays | Buy Maintains $16 → $17 | Buy | Maintains | $16 → $17 | +25.81% | Jul 30, 2024 |
| Barclays | Barclays | Buy Maintains $16 → $16 | Buy | Maintains | $16 → $16 | +17.14% | May 8, 2024 |
| Barclays | Barclays | Buy Maintains $15 → $16 | Buy | Maintains | $15 → $16 | +15.69% | Jan 29, 2024 |
| Barclays | Barclays | Buy Maintains $13 → $14 | Buy | Maintains | $13 → $14 | +1.23% | Jun 1, 2023 |
Financial Forecast
Revenue This Year
328.68B
from 279.16B
Increased by 17.74%
Revenue Next Year
359.32B
from 328.68B
Increased by 9.32%
EPS This Year
68.63
from 66.80
Increased by 2.73%
EPS Next Year
72.80
from 68.63
Increased by 6.08%
Financial currency is INR. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 343.6B | 391.8B | 394.9B | ||
| Avg | 328.7B | 359.3B | 355.4B | ||
| Low | 266.7B | 309.2B | 318.7B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 23.1% | 19.2% | 9.9% | ||
| Avg | 17.7% | 9.3% | -1.1% | ||
| Low | -4.5% | -5.9% | -11.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 75.60 | 93.45 | 86.28 | |
| Avg | 68.63 | 72.80 | 58.36 | |
| Low | 46.45 | 58.02 | 34.59 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 13.2% | 36.2% | 18.5% | |
| Avg | 2.7% | 6.1% | -19.8% | |
| Low | -30.5% | -15.5% | -52.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.